BEFORE THE IOWA BOARD OF PHARMACY

RE:

Controlled Substances Act Registration of

ANDREA L. VENTEICHER, MD Registration No. 1241130 Respondent CASE NO. 2019-0065

COMBINED STATEMENT OF CHARGES, SETTLEMENT AGREEMENT, AND FINAL ORDER

COME NOW the Iowa Board of Pharmacy ("Board") and Andrea L. Venteicher, MD, ("Respondent"), 46 E Main St, Waterville IA 52170, and enter into this Combined Statement of Charges, Settlement Agreement, and Final Order ("Order") pursuant to Iowa Code sections 17A.10, 124.305, and 272C.3(4) (2018). The Board has jurisdiction over Respondent and the subject matter of this case pursuant to Iowa Code chapters 17A, 124, and 272C, and 657 IAC chapter 10.

A. STATEMENT OF CHARGES

COUNTI

DISCIPLINARY ACTION AGAINST PROFESSIONAL LICENSE

1. Respondent is charged with having her professional license disciplined in a way that restricts her ability to handle or prescribe controlled substances, pursuant to lowa Code section 124.304(1)(e) and 657 IAC 10.10(1)"e".

B. FACTUAL CIRCUMSTANCES

- 2. Respondent holds Iowa Controlled Substances Act (CSA) registration number 1241130, which is currently active through May 31, 2021.
- 3. On May 9, 2019, the lowa Board of Medicine approved a Combined Statement of Charges and Settlement Agreement that imposed discipline on Respondent's medical license for failure to provide appropriate pain management. Under the Agreement, Respondent agreed to refrain from prescribing, administering, or dispensing controlled substances for the treatment of chronic pain under her lowa medical license.

C. SETTLEMENT AGREEMENT AND FINAL ORDER

- 4. The Board has jurisdiction over the parties and the subject matter of this proceeding.
- 5. Without admitting wrongdoing, Respondent acknowledges that the allegations in the Statement of Charges, if proven in a contested case hearing, could constitute grounds for the discipline agreed to in this Order.

- 6. Execution of this Order constitutes the resolution of a contested case. Respondent has a right to a hearing before the Board on the charges, but Respondent waives the right to hearing and all attendant rights, including the right to appeal or seek judicial review of the Board's action, by freely and voluntarily entering into this Order. Once entered, this Order shall have the force and effect of a disciplinary order entered following a contested case hearing.
- 7. Respondent acknowledges that she has the right to be represented by counsel on this matter.
- 8. This Order is subject to approval by a majority of the full Board. If the Board does not approve this Order, it shall be of no force or effect to either party, and shall not be admissible for any purpose in further proceedings in this matter. If the Board approves this Order, it shall be the full and final resolution of this matter.
- This Order shall be part of Respondent's permanent record and shall be considered by the Board in determining the nature and severity of any disciplinary action to be imposed in the event of any future violations.
- 10. Respondent understands the Board is required by federal law to report any adverse action to the National Association of Boards of Pharmacy's Disciplinary Clearinghouse and the National Practitioner Data Bank. Respondent has been informed, and the Board acknowledges, that this reporting is intended not as a new disciplinary action, but as a reciprocal action based off an underlying disciplinary order.
- 11. This Order, when fully executed, is a public record and is available for inspection and copying in accordance with the requirements of lowa Code chapters 22 and 272C.
 - 12. The Board's approval of this Order shall constitute a FINAL ORDER of the Board.

IT IS THEREFORE ORDERED:

- 13. Respondent CSA registration is hereby RESTRICTED to prohibit Respondent from prescribing, administering, or dispensing controlled substances for the treatment of chronic pain as defined by the lowa Board of Medicine. Nothing contained herein shall be construed to restrict or prohibit Respondent from prescribing, administering or dispensing controlled substances for the treatment of pain in acute care settings.
- 14. If the Iowa Board of Medicine permits Respondent to prescribe, administer, or dispense controlled substances for the treatment of chronic pain in the future, Respondent shall notify the Iowa Board of Pharmacy. Respondent's CSA registration shall remain restricted until such notification occurs.
 - 15. Respondent shall provide a copy of this Order to any employers.

16. Should Respondent violate the terms of this Order, the Board may initiate action to suspend or revoke Respondent's CSA registration as authorized by lowa Code chapter 124 and 657 IAC chapter 10.

ANDREA L. VENTEICHER, MD
Respondent

This Combined Statement of Charges, Settlement Agreement, and Final Order is approved by the lowa Board of Pharmacy on theuth day of November 2019.

Acting Chairperson

Iowa Board of Pharmacy